



To: MaineCare Providers
From: Anne-Marie Toderico, Director of Pharmacy
Date: January 14, 2022
Re: PDL Update for **01/14/2022**

MaineCare PDL Update for January 14, 2022

The following medication(s) have been recently added/changed to the MaineCare PDL as **non-preferred** and will require prior authorization.

- Aemcolo
- Exkivity
- Invega Hafyera
- Loreev XR
- Lybalvi
- Qulipta
- Saphnelo
- Thyquidity
- Trudhesa
- Welireg

The following medication(s) have recently been added to the MaineCare PDL as **non-preferred** and with new PDL criteria:

- Azstarys: For the treatment of patients ≥ 6 years of age.
- Bylvay: For the treatment of patients ≥ 3 months of age. Clinical PA required for appropriate diagnosis.
- Livmarli: Clinical PA required for appropriate diagnosis.
- Nexviazyme: For patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
- Rezurock: For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least 2 prior lines of systemic therapy.
- Opzelura: For the treatment of patients ≥ 12 years of age.
- Winlevi: Not approved for use in children <12 years of age